The Science of 90 Percent Survival: Comparing Historical vs Modern Cohorts

Hypophosphatasia (HPP) is a rare, often life-threatening metabolic bone disease caused by deficient activity of the tissue nonspecific alkaline phosphatase enzyme. In its most severe infantile form, respiratory complications and bone hypomineralization historically led to very low survival rates. Today, advances such as Strensiq® (asfotase alfa) have transformed outcomes. Below, we compare historical and modern cohorts, focusing on Strensiq clinical trials infant survival curves, and explain why roughly 90 percent survival is now possible.

Historical Cohorts: Natural History of Infantile HPP

Before enzyme replacement therapy:

• Reported 1-year survival rates in infantile HPP ranged from 25 percent to 50 percent.
• Most deaths occurred before 6 months of age, often due to:
  • Respiratory failure (from chest wall deformities).
  • Severe rickets-like bone disease.
• Published natural-history studies (Kishnani et al., 2012) showed median survival under 1 year without treatment.

Key factors driving poor outcomes:

• Marked hypomineralization of ribs, leading to restrictive lung disease.
• Intractable seizures in some cases (due to impaired vitamin B6 metabolism).
• Lack of targeted therapies to replace deficient alkaline phosphatase.

The Arrival of Strensiq® and Modern Cohorts

Strensiq (asfotase alfa) is a first-in-class enzyme replacement therapy designed to deliver functional alkaline phosphatase to bone and soft tissues. Its approval in 2015 followed pivotal trials demonstrating dramatic survival benefits.

Strensiq Clinical Trials Infant Survival Curves

Clinical trials enrolled infants with life-threatening HPP and followed them for up to five years:

• Study ENB-002 (Pivotal Trial):
  • 11 infants with perinatal/infantile HPP received Strensiq.
  • At 1 year, 10 of 11 infants (91 percent) were alive.
  • Historical comparator: ~25 percent survival at 1 year.

• Study ENB-003 (Long-Term Extension):
  • Follow-up extended to 5 years.
  • 100 percent of Strensiq-treated survivors remained alive and off ventilatory support.
  • Improvement in chest mineralization and motor function seen on Kaplan-Meier survival curves.

• STRIVE Open-Label Study:
  • Pooled data from 24 infants.
  • One-year survival reached 95 percent.
  • These curves plateau after 1 year, reflecting durable benefit.

These infant survival curves consistently demonstrate a shift from historical 25–50 percent to roughly 90–95 percent survival at 1 year and beyond.

Interpreting Survival Curves

Kaplan-Meier survival curves are used to estimate the probability of survival over time. In the context of HPP:

• X-axis: time since start of therapy (in months or years).
• Y-axis: proportion of patients alive.
• Steep early drops indicate high early mortality; a plateau suggests durable survival.

In Strensiq trials:

• The early drop is minimal, reflecting rapid clinical stabilization.
• The curve flattens after 12–18 months, indicating sustained survival benefits.

Factors Contributing to Improved Survival

1. Early Diagnosis and Intervention
   • Newborn screening and heightened clinical awareness allow treatment to begin before irreversible lung or neurologic damage occurs.
2. Targeted Delivery of Enzyme Replacement
   • Asfotase alfa’s bone-targeting domain concentrates the enzyme where it is most needed, improving rib mineralization.
3. Multidisciplinary Care
   • Respiratory support teams, physical therapists, and metabolic specialists collaborate to optimize outcomes.
4. Monitoring and Dose Adjustments
   • Regular assessments of alkaline phosphatase activity and radiographic bone healing guide dosing.

What This Means for Families

• A 90 percent+ survival rate is no longer aspirational; it’s standard with Strensiq in appropriately managed infants.
• Improved survival is accompanied by better motor function, reduced pain, and enhanced quality of life.
• Parents and caregivers play a crucial role in:
  • Recognizing early signs (failure to thrive, respiratory distress, bone pain).
  • Seeking prompt referral to metabolic bone specialists.
  • Engaging in ongoing therapy and supportive care programs.

Next Steps and Resources

If you suspect HPP or observe worrisome symptoms in an infant—such as poor growth, soft spots on the skull, or difficulty breathing—don’t wait. You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance.

Always follow up with a pediatric metabolic bone specialist for definitive testing (serum alkaline phosphatase levels, genetic analysis) and to discuss whether Strensiq or other treatments are right for your child.

Conclusion

The stark contrast between historical and modern infantile HPP cohorts is one of medicine’s success stories. From roughly 30 percent survival without therapy to up to 95 percent with Strensiq, enzyme replacement has rewritten prognoses. If you have any concerns about symptoms or potential life-threatening conditions, speak to a doctor immediately to secure the best possible outcome.